VolitionRx Limited (VNRX)

ASE – Цена в реальном времени. Валюта: USD

0.66

-0.05 (-7.58%)

При закрытии: Aug 12, 2026, 3:59 PM EDT

0.65

-0.02 (-2.39%)

После закрытия: Aug 12, 2026, 4:55 PM EDT

12.08.2026

Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients

Removes Centralized Lab Dependency for $3.8 Billion Global Addressable Market for NETosis Testing HENDERSON, Nev., Aug. 12, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that results utilizing its lateral flow prototype are highly correlated with results utilizing Volition's established automated Nu.Q® NETs test in critically ill sepsis patients1 , thereby expanding beyond centralized laboratory testing.

11.08.2026

VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update

Conference call to take place on Friday, August 14 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.

05.08.2026

Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology

Targets $36 Billion TAM in Early Cancer Detection and MRD. Company in active discussions with global diagnostic leaders to accelerate commercialization.

Видео

No Data

There is no data to display

Пресс-релизы

12.08.2026

Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients

05.08.2026

Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology

Targets $36 Billion TAM in Early Cancer Detection and MRD. Company in active discussions with global diagnostic leaders to accelerate commercialization.

VolitionRx Limited (VNRX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

VolitionRx Limited (VNRX)

Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients

VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update

Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology

Видео

No Data

Пресс-релизы

Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients

Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology

Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients

VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update

Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology

Видео

No Data

Пресс-релизы

Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients

Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology

Search stocks

VolitionRx Limited (VNRX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

VolitionRx Limited (VNRX)

Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients

VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update

Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology

Видео

No Data

Пресс-релизы

Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients

Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology

Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients

VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update

Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology

Видео

No Data

Пресс-релизы

Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients

Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology